Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on symptoms relief. Over the past few years, stem cell research has expanded greatly as a tool for developing new therapies to treat incurable diseases. Stem cell therapy has been shown as promising in several animal ALS models and human clinical trials.
Subjects will be assigned to autologous mesenchymal stromal cell (AMSC) treatment according to inclusion and exclusion criteria (see below) screened four times prior to administration. Then the subjects will be observed for three consecutive yearsAfter a half year of screening period, the autologous multipotent mesenchymal stromal cells from bone marrow will be isolated. The cells will be cultivated for 3 passages (3 - 4 weeks) in order to get sufficient amount for therapy, cell suspension for intrathecal application will be prepared and introduced intrathecally through lumbar puncture. Subsequently, all the subjects will be observed at the range of standard medical care used at these types of interventions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
26
Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events
Complications at the site of intrathecal infusion of the medicinal product and no new neurological deficit (meningism, paraplegia, urinary incontinence) not attributed to the natural progression of the ALS disease will be recorded at Visits I, III, IV, V, VI, and IX. Occurrence of other potential adverse events, including headache, respiratory failure, leukocytosis, cervical spine stenosis, cystitis and hyperhydrosis will be evaluated on the severity scale (1=mild, 2=moderate, 3=severe). Brain and spinal cord MRI will be performed at Visits I and IX to exclude treatment-related tumor formation, pathological contrast enhancement or other structural pathology.
Time frame: 1 year
Efficacy: Inhibition of the disease progression - ALS functional rating scale
Inhibition of the disease progression will be recorded by ALS functional rating scale (ALSFRS) at Visits I, III, and VI through X. Measures (all 4-0): 1. speech 2. salivation 3. swallowing 4. handwriting 5. cutting food and handling utensils (with or without gastrostomy) 6. dressing and hygiene 7. turning in bed and adjusting bed clothes 8. walking 9. climbing stairs 10. breathing ALSFRS = SUM (points for all 10 measures) Interpretation: minimum score: 0 maximum score: 40 The higher the score the more function is retained.
Time frame: 18 months
Efficacy: Inhibition of the disease progression - Norris scale
Inhibition of the disease progression will be recorded by Norris scale at Visits I, III, and VI through X. Norris scal has has 22 items examining bulbar, respiratory, trunk, arm, leg, and general domains involving reflexes, fasciculation, and muscle atrophy. The scale also measures emotional lability, fatigability and leg rigidity. The Norris scale has a linear decline during the course of ALS.
Time frame: 18 months
Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)
FVC (%) will be measured at Visits I, and VI through X.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.